a reduced fertilizer forecast and downgrades Potash (NYSE: POT ) to Underperform from Market Perform as well as Mosaic (NYSE: MOS ) to Sector Perform from Outperform; POT -1% premarket. Also: CF , AGU , IPI , RNF . Post your comment!
planned clinical studies to evaluate the combination of Gazyva and IPI -145 (duvelisib) as a treatment for patients with blood cancers ..... consummate a material transfer agreement whereby Infiniti will supply IPI -145 to Roche to use in its preclinical and translational research
NYSE: ABBV ) and Infinity Pharmaceuticals (NASDAQ: INFI ) enter into a global collaboration to develop and commercialize IPI -145 ( duvelisib ), an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment
We are dropping analyst coverage of Intrepid Potash . We provide broad coverage of more than 1,500 companies across more than 90 industry groups and adjust our coverage as necessary based on client demand and investor interest.
Millennium Pharmaceuticals for sales of IPI -145, Infinity's oral PI3K inhibitor ..... to Millennium future royalties related to IPI -145 in oncology. Infinity may exercise ..... that gain regulatory approval, including IPI -145. The remaining payments include up
cancers, several competitors are following close behind. Gilead's idelalisib has recently been approved and Infinity's IPI -145, and AbbVie/Roche's ABT-199 are in Phase III studies. Earlier-stage Ono Pharmaceutical's ONO-4059 and Celgene's
but we'll be keeping an eye out to make sure management doesn't make a habit out of raising project cost estimates. Intrepid Potash is a U.S. producer of potash (1,000,000 tons of capacity) and langbeinite (240,000 tons of capacity) operating
We’re raising our fair value estimate for Intrepid Potash to $16 per share from $15 per share following the release of second-quarter results. Our fair value estimate boost reflects
We're holding steady on our $15-per-share fair value estimate for Intrepid Potash following the release of the company's first-quarter results. Our no-moat rating remains intact. Despite a big jump in
heavily on fertilizer mix at the individual company level. For example, the effect will be much greater on pure-play Intrepid Potash than diversified Agrium. We also expect to re-examine other parts of our valuations for potash producers when implementing